Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at ...

iOnctura has announced the appointment Steven Sciuto as its new Chief Financial Officer. Sciuto holds over 15 years of ...

Zusduri, which is delivered directly into the bladder in an out-patient procedure, is now the first and only medication approved by the US regulator to treat adults with recurrent low-grade ...

EMHA calls for its inclusion in EU neurological health strategy The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine in the forthcoming Neurological Health ...

Biotech firm shares phase 2 findings on novel osteoarthritis treatmen Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The first ...